Trials / Completed
CompletedNCT01719783
Reactogenicity, Safety, and Immunogenicity of a Live Monovalent H5N2 Influenza Vaccine
Reactogenicity, Safety and Immunogenicity of a Live Monovalent A/17/Turkey/Turkey/05/133 (H5N2) Influenza Vaccine
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- PATH · Academic / Other
- Sex
- All
- Age
- 18 Years – 49 Years
- Healthy volunteers
- Accepted
Summary
To evaluate the safety profile of two intranasal doses of LAIV A/17/turkey/Turkey/05/133 (H5N2) in healthy adults.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | LAIV H5N2 | 2 doses provided intranasally |
| OTHER | Placebo | 2 doses of placebo provided intranasally |
Timeline
- Start date
- 2012-09-01
- Primary completion
- 2013-01-01
- Completion
- 2013-01-01
- First posted
- 2012-11-01
- Last updated
- 2018-11-28
- Results posted
- 2018-11-28
Locations
1 site across 1 country: Russia
Source: ClinicalTrials.gov record NCT01719783. Inclusion in this directory is not an endorsement.